Bristol-Myers Squibb has cancelled development of Medivir‘s preclinical HIV compound MIV-170. The compound did not meet the BMS’s desired profile, according to a Medivir statement. MIV-170 belongs to the group of polymerase inhibitors that Medivir already discontinued the development of and that are administered by the subsidiary Medivir HIV Franchise AB. “Everyone is aware of the obvious risks in early pharmaceutical development. MIV-170 has not yet reached clinical develop...